Karen Read continues to fight the O'Keefe family in court, and new filings indicate that a recent mistake could be a new ...

Lawyers for Karen Read are trying to force lawyers representing the family of her boyfriend, Boston Police officer John ...

A judge denied a motion from the special prosecutor handling the witness intimidation cases against Aidan Kearney to search two phones Karen Read used to communicate with the blogger, Read’s lawyer ...

GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions. Rapt only licensed the therapy, called ozureprubart, from ...

Drugmaker GSK said it agreed to acquire Californian biopharmaceutical company RAPT Therapeutics RAPT0.07%increase; green up pointing triangle for around $2.2 billion, a move set to bolster its ...

GSK gains global rights to ozureprubart, excluding parts of Asia RAPT's ozureprubart targets antibody causing allergic reactions Deal is GSK's first major acquisition under new CEO Luke Miels The deal ...

Fintel reports that on January 20, 2026, TD Cowen downgraded their outlook for RAPT Therapeutics (NasdaqGM:RAPT) from Buy to Hold. Analyst Price Forecast Suggests 9.67% Upside As of January 14, 2026, ...

GSK’s presence in immunology and inflammation is heavily oriented around respiratory drugs, but the company has been expanding its scope through business deals. The pharmaceutical giant is now adding ...

GSK Plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will ...

The last time I spoke about RAPT Therapeutics, Inc. (RAPT), it was in a Seeking Alpha article entitled "RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus." With respect to this article, I ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would buy RAPT Therapeutics in a deal worth ...